Brian Goff - Net Worth and Insider Trading

Brian Goff Net Worth

The estimated net worth of Brian Goff is at least $13 Million dollars as of 2026-08-11. Brian Goff is the EVP & Chief Commercial Officer of Alexion Pharmaceuticals Inc and owns about 36,257 shares of Alexion Pharmaceuticals Inc (ALXN) stock worth over $7 Million. Brian Goff is also the CEO of Agios Pharmaceuticals Inc and owns about 184,508 shares of Agios Pharmaceuticals Inc (AGIO) stock worth over $6 Million. Details can be seen in Brian Goff's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Brian Goff has not made any transactions after 2026-04-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Brian Goff

Are these stocks worth buying? — GuruFocus analysis for each holding

- GF

ALXN Alexion Pharmaceuticals Inc

52% of holdings · $6.6M

AGIO Agios Pharmaceuticals Inc

48% of holdings · $6.0M

Brian Goff Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Brian Goff owns 4 companies in total, including Alexion Pharmaceuticals Inc (ALXN) , Baxalta Inc (BXLT) , and Agios Pharmaceuticals Inc (AGIO) among others .

Click here to see the complete history of Brian Goff’s form 4 insider trades.

Insider Ownership Summary of Brian Goff

Ticker	Company	Transaction Date	Type of Owner
ALXN	Alexion Pharmaceuticals Inc	2020-06-08	EVP & Chief Commercial Officer
BXLT	Baxalta Inc	2016-06-03	EVP and President & Hematology
AGIO	Agios Pharmaceuticals Inc	2026-04-02	director & Chief Executive Officer
		2024-06-13	director

Brian Goff Latest Holdings Summary

Brian Goff currently owns a total of 2 stocks. Among these stocks, Brian Goff owns 36,257 shares of Alexion Pharmaceuticals Inc (ALXN) as of June 8, 2018, with a value of $7 Million and a weighting of 52.38%. Brian Goff also owns 184,508 shares of Agios Pharmaceuticals Inc (AGIO) as of April 2, 2026, with a value of $6 Million and a weighting of 47.62%.

Latest Holdings of Brian Goff

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ALXN	Alexion Pharmaceuticals Inc	2018-06-08	36,257	182.50	6,616,903
AGIO	Agios Pharmaceuticals Inc	2026-04-02	184,508	32.61	6,015,883

Holding Weightings of Brian Goff

Brian Goff Form 4 Trading Tracker

According to the SEC Form 4 filings, Brian Goff has made a total of 0 transactions in Alexion Pharmaceuticals Inc (ALXN) over the past 5 years. The most-recent trade in Alexion Pharmaceuticals Inc is the sale of 1,645 shares on June 8, 2018, which brought Brian Goff around $194,982.

According to the SEC Form 4 filings, Brian Goff has made a total of 11 transactions in Agios Pharmaceuticals Inc (AGIO) over the past 5 years, including 0 buys and 11 sells. The most-recent trade in Agios Pharmaceuticals Inc is the sale of 19,068 shares on April 2, 2026, which brought Brian Goff around $661,850.

Insider Trading History of Brian Goff

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Brian Goff Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Get the full picture on these stocks

See GF Score, valuation, financials, and warning signs for every stock Brian Goff owns.

- ALXN - AGIO

View ALXN Analysis

Brian Goff Ownership Network

Ownership Network List of Brian Goff

No Data

Ownership Network Relation of Brian Goff

Brian Goff Owned Company Details

What does Alexion Pharmaceuticals Inc do?

Who are the key executives at Alexion Pharmaceuticals Inc?

Brian Goff is the EVP & Chief Commercial Officer of Alexion Pharmaceuticals Inc. Other key executives at Alexion Pharmaceuticals Inc include SVP & Controller & CAO Daniel Bazarko , EVP & CCAO Tanisha Carino , and EVP & Research & Development John J Orloff .

Alexion Pharmaceuticals Inc (ALXN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Alexion Pharmaceuticals Inc (ALXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Alexion Pharmaceuticals Inc (ALXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Alexion Pharmaceuticals Inc (ALXN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alexion Pharmaceuticals Inc Insider Transactions

No Available Data

What does Baxalta Inc do?

Who are the key executives at Baxalta Inc?

Brian Goff is the EVP and President & Hematology of Baxalta Inc. Other key executives at Baxalta Inc include EVP & Head of Human Resources Anne-marie Law , See Remarks John J Orloff , and director & President and CEO Ludwig Hantson .

Baxalta Inc (BXLT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Baxalta Inc (BXLT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Baxalta Inc (BXLT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Baxalta Inc (BXLT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Baxalta Inc Insider Transactions

No Available Data

What does Agios Pharmaceuticals Inc do?

Who are the key executives at Agios Pharmaceuticals Inc?

Brian Goff is the director & Chief Executive Officer of Agios Pharmaceuticals Inc. Other key executives at Agios Pharmaceuticals Inc include Chief Medical Officer Sarah Gheuens , Chief Legal Officer James William Burns , and Chief Corp Dev & Strategy Krishnan Viswanadhan .

Agios Pharmaceuticals Inc (AGIO) Insider Trades Summary

Over the past 18 months, Brian Goff made 5 insider transaction in Agios Pharmaceuticals Inc (AGIO) with a net sale of 85,611. Other recent insider transactions involving Agios Pharmaceuticals Inc (AGIO) include a net sale of 68,804 shares made by Sarah Gheuens , a net sale of 16,385 shares made by Tsveta Milanova , and a net sale of 18,234 shares made by James William Burns .

In summary, during the past 3 months, insiders sold 34,007 shares of Agios Pharmaceuticals Inc (AGIO) in total and bought 0 shares, with a net sale of 34,007 shares. During the past 18 months, 237,229 shares of Agios Pharmaceuticals Inc (AGIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 237,229 shares.

Agios Pharmaceuticals Inc (AGIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Agios Pharmaceuticals Inc Insider Transactions

No Available Data

What does Intellia Therapeutics Inc do?

Who are the key executives at Intellia Therapeutics Inc?

Brian Goff is the director of Intellia Therapeutics Inc. Other key executives at Intellia Therapeutics Inc include EVP & Chief Financial Officer Dulac Edward J Iii , Principal Accounting Officer Michael P Dube , and EVP & Chief Technical Officer Eliana Clark .

Intellia Therapeutics Inc (NTLA) Insider Trades Summary

Over the past 18 months, Brian Goff made no insider transaction in Intellia Therapeutics Inc (NTLA). Other recent insider transactions involving Intellia Therapeutics Inc (NTLA) include a net sale of 26,629 shares made by Dulac Edward J Iii , a net sale of 10,004 shares made by Michael P Dube , and a net sale of 11,144 shares made by Eliana Clark .

In summary, during the past 3 months, insiders sold 15,429 shares of Intellia Therapeutics Inc (NTLA) in total and bought 0 shares, with a net sale of 15,429 shares. During the past 18 months, 195,081 shares of Intellia Therapeutics Inc (NTLA) were sold and 250,000 shares were bought by its insiders, resulting in a net purchase of 54,919 shares.

Intellia Therapeutics Inc (NTLA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Intellia Therapeutics Inc Insider Transactions

No Available Data

Brian Goff Mailing Address

Above is the net worth, insider trading, and ownership report for Brian Goff. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Brian Goff's mailing address is: Cambridge Ct 02139.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.